PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
44 hedge funds and large institutions have $3.1M invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
2% more funds holding
Funds holding: 43 → 44 (+1)
19% less capital invested
Capital invested by funds: $3.83M → $3.1M (-$724K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$191K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$108K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$17.1K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$8.98K |
| 5 |
Renaissance Technologies
New York
|
+$8.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$465K |
| 2 |
Goldman Sachs
New York
|
-$95.6K |
| 3 |
Millennium Management
New York
|
-$55.8K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$26.5K |
| 5 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$11K |
PVCT Hedge Fund Activity: Q1 2016 in Review
44 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q1 2016, worth a combined $3.1M — down 19% from $3.83M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PVCT positions and 4 closed out — a net gain of 1 holder — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $191K. The largest seller was Sabby Management, cutting an estimated $465K.
- 44 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q1 2016, up from 43 in Q4 2015.
- Funds reported $3.1M of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q1 2016, down 19% quarter-over-quarter.
- 5 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q1 2016 and 4 closed out, a net change of +1 holder.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q1 2016 was Vanguard Group, an estimated $191K added.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q1 2016 was Sabby Management, an estimated $465K sold.
Based on aggregated 13F filings for Q1 2016.